Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQQA9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,474
Award facts
- Contract value 100% obligated
- $17,474.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $17,474.40 by the Defense Logistics Agency on January 9, 2026, for the supply of Xolair 300 mg/2 ml auto-injector vials. This delivery order carries no set-aside designation, indicating the award was made through full and open competition. The product will be delivered to the Park Ridge, IL location, with an ultimate completion date of February 2, 2026. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (SPE2DR) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded in November 2025 with a $499.999 billion ceiling value extending through December 2036.
The PPV-G GEN V program represents a $30.3 billion Department of Defense acquisition strategy designed to establish multiple regional prime vendor contractors for supplying pharmaceuticals and medical consumables to military healthcare facilities worldwide. DMS Pharmaceutical Group's contract encompasses a 30-month base period with three optional 30-month renewal periods, positioning the company as a critical supplier for DoD healthcare operations globally. The company's substantial federal contracting activity and demonstrated performance across diverse pharmaceutical categories—including specialty biologics, oncology treatments, vaccines, and routine medications—supports its role as an established prime vendor within the Defense Logistics Agency's medical supply chain infrastructure.
Quick answers
Who was awarded contract SPE2DR26FQQA9?
SPE2DR26FQQA9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 9, 2026.
How much is contract SPE2DR26FQQA9 worth?
The government has obligated $17,474 on SPE2DR26FQQA9.
Is contract SPE2DR26FQQA9 an order under another contract?
Yes. SPE2DR26FQQA9 is a delivery order under SPE2DR25D9331, an indefinite delivery contract.
Was contract SPE2DR26FQQA9 competed?
The extent of competition for SPE2DR26FQQA9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award